Welcome to our dedicated page for BioAge Labs news (Ticker: BIOA), a resource for investors and traders seeking the latest updates and insights on BioAge Labs stock.
BioAge Labs Inc. (BIOA) is a clinical-stage biopharmaceutical company developing therapies targeting aging biology to treat metabolic diseases and neuroinflammation. This page provides investors and industry professionals with verified updates on the company’s progress, including clinical trial developments, strategic partnerships, and regulatory milestones.
Access the latest press releases and news articles covering BIOA’s pipeline advancements, such as its apelin receptor agonist Azelaprag (BGE-105) for obesity and BGE-100 for neuroinflammatory conditions. Stay informed about preclinical research outcomes, financial disclosures, and collaborations shaping the company’s innovative approach to age-related diseases.
Key updates include trial phase results, FDA communications, and analyses of BIOA’s unique position in the competitive biopharma landscape. Bookmark this page for real-time insights into how BioAge Labs leverages aging biology to address complex health challenges.
BioArctic's partner, Eisai, projects Leqembi® sales to reach JPY 56.5 billion (approx. SEK 4 billion) for FY 2024 (April 2024 - March 2025), generating SEK 360 million in net royalties for BioArctic. For FY 2023, Leqembi sales were JPY 4.3 billion, resulting in SEK 28.2 million in royalties. BioArctic holds commercialization rights for lecanemab in the Nordic region, pending European approval. The first-quarter report for 2024 will be released on May 17, 2024. The disclosed information complies with the EU Market Abuse Regulation.
Eisai has initiated a rolling submission of a Biologics License Application (BLA) to the U.S. FDA for Leqembi® (lecanemab-irmb) subcutaneous maintenance dosing. This follows the FDA granting Fast Track designation to Leqembi for Alzheimer's disease treatment in early AD stages. Currently approved for biweekly intravenous (IV) treatment, Leqembi's subcutaneous autoinjector simplifies home treatment, reducing the need for hospital visits. The BLA relies on Phase 3 Clarity AD open-label extension study data and aims to maintain effective drug concentrations to sustain clearance of toxic protofibrils. Leqembi is already approved in the US, Japan, and China, with additional applications under review globally. Eisai leads the global development and regulatory submissions, while BioArctic holds commercialization rights in the Nordic region pending European approval.
FAQ
What is the current stock price of BioAge Labs (BIOA)?
What is the market cap of BioAge Labs (BIOA)?
